The role of intermittent androgen deprivation in prostate cancer.
Boccon-Gibod
Laurent
L
Department of Urology, Hôpital Bichat, Paris, France. laurent.boccon-gibod@bch.ap-hop-paris.fr
Hammerer
Peter
P
Madersbacher
Stephan
S
Mottet
Nicolas
N
Prayer-Galetti
Tommaso
T
Tunn
Ulf
U
D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D000728:Androgens / Q000378:metabolism; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011788:Quality of Life; D016896:Treatment Outcome
D000726:Androgen Antagonists; D000728:Androgens; D018931:Antineoplastic Agents, Hormonal